Neuroscience company is on the mend
This developer of digital solutions to assess brain health has seen its shares tumble on widening losses and the unexpeceted requirement of a new high-cost loan. The latest trading update suggest that costs are under control and new products offer encouragement. Shareholders will need to be patient, but the valuation looks appealing. (IHT qualifying)
According to the World Health Organisation, disorders of the brain, such as Alzheimer’s disease, Schizophrenia, Parkinson’s, depression and mental illness, are the world’s primary cause of ill health, resulting in higher costs and more hospitalisations than any other disease group.
Early diagnosis of brain illnesses is desirable as it can help to reduce the costs associated with Alzheimer’s disease and dementia.
Cambridge Cognition Holdings (AIM: COG) is a highly innovative AIM listed digital health technology company,…
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
- Podcasts
Previous article Next article
